All In Biotech

Drug Trial Radar · NCT02411955

A Study Comparing Tazarotene Cream 0.1% to Tazorac® and Both to a Placebo Control in the Treatment of Acne Vulgaris

A Multiple-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study Comparing Tazarotene Cream 0.1% to Tazorac® (Tazarotene Cream 0.1%) and Both Active Treatments to a Placebo Control in the Treatment of Acne Vulgaris

Last checked: Nov 19, 2026Latest source record: May 4, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 1,077 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,077

Actual

Start

Jun 2014

Primary completion

Jan 2015

Study completion Feb 2015

Sponsor

Sponsor type
Industry
First posted
Apr 8, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 12 years, up to 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the therapeutic equivalence and safety of Tazarotene Cream 0.1% and Tazorac® (tazarotene cream 0.1%).

Conditions

  • Acne Vulgaris

Interventions

  • Tazarotene Cream 0.1%Drug

    Tazarotene Cream 0.1% applied to lightly cover the entire face once daily for 84 consecutive days.

  • Tazorac®Drug

    Tazorac® applied to lightly cover the entire face once daily for 84 consecutive days.

  • PlaceboDrug

    Placebo (vehicle of the test product) applied to lightly cover the entire face once daily for 84 consecutive days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in inflammatory lesion countsTime frame: Week 12
  2. Change in non-inflammatory lesion countsTime frame: Week 12

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.